UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

Muscle & nerve, 2018-05, Vol.57 (5), p.829-837

2018

Volltextzugriff (PDF)

"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy

Journal of the peripheral nervous system, 2016-03, Vol.21 (1), p.5-9

2016

Volltextzugriff (PDF)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series

Orphanet journal of rare diseases, 2019-02, Vol.14 (1), p.34-7, Article 34

2019

Volltextzugriff (PDF)

Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years

Amyloid, 2017-07, Vol.24 (3), p.194-204

2017

Volltextzugriff (PDF)

Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

PloS one, 2024-01, Vol.19 (1), p.e0292435-e0292435

2024

Volltextzugriff (PDF)

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

Orphanet journal of rare diseases, 2022-06, Vol.17 (1), p.1-236, Article 236

2022

Volltextzugriff (PDF)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Journal of the peripheral nervous system, 2021-06, Vol.26 (2), p.160-166

2021

Volltextzugriff (PDF)

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Orphanet journal of rare diseases, 2023-11, Vol.18 (1), p.1-350, Article 350

2023

Volltextzugriff (PDF)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Orphanet journal of rare diseases, 2018-12, Vol.13 (1), p.225-225, Article 225

2018

Volltextzugriff (PDF)

Buprenorphine Use: The International Experience

Clinical infectious diseases, 2006-12, Vol.43 (Supplement-4), p.S197-S215

2006

Volltextzugriff (PDF)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Muscle & nerve, 2016-09, Vol.54 (3), p.353-360

2016

Volltextzugriff (PDF)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Cardiology and therapy, 2024-06, Vol.13 (2), p.359-368

2024

Volltextzugriff (PDF)

Contingency management among homeless, out-of-treatment men who have sex with men

Journal of substance abuse treatment, 2010-10, Vol.39 (3), p.255-263

2010

Volltextzugriff (PDF)

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

JACC. Advances (Online), 2024-08, Vol.3 (8), p.101086, Article 101086

2024

Volltextzugriff (PDF)

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

Cardiology and therapy, 2024-03, Vol.13 (1), p.117-135

2024

Volltextzugriff (PDF)

Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis

JACC. Heart failure, 2021-10, Vol.9 (10), p.736-746

2021

Volltextzugriff (PDF)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy

Neurology and therapy, 2020-06, Vol.9 (1), p.135-149

2020

Volltextzugriff (PDF)

A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment

Journal of substance abuse treatment, 2008-03, Vol.34 (2), p.208-214

2008

Volltextzugriff (PDF)

Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial

Amyloid, 2017-01, Vol.24 (1), p.30-36

2017

Volltextzugriff (PDF)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Amyloid, 2016-07, Vol.23 (3), p.178-183

2016

Volltextzugriff (PDF)

Using buprenorphine short-term taper to facilitate early treatment engagement

Journal of substance abuse treatment, 2007-06, Vol.32 (4), p.349-356

2007

Volltextzugriff (PDF)

Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Journal of cardiac failure, 2024-06

2024

Volltextzugriff (PDF)

Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation

Journal of substance abuse treatment, 2007-03, Vol.32 (2), p.167-175

2007

Volltextzugriff (PDF)

A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Amyloid, 2022-10, Vol.29 (4), p.228-236

2022

Volltextzugriff (PDF)

The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy

Current medical research and opinion, 2020-05, Vol.36 (5), p.799-808

2020

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(75)
Dissertationen
(1)

Sprache

Englisch
(76)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Humans
(44)
Male
(34)
Female
(30)
Adult
(29)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Psychiatry
(21)
Substance Abuse
(20)
Amyloidosis
(19)
Middle Aged
(19)
Buprenorphine
(15)
Psychology. Psychoanalysis. Psychiatry
(15)
Psychopathology. Psychiatry
(15)
Transthyretin
(15)
Drug Abuse
(14)
Toxicology
(14)
Buprenorphine - Administration & Dosage
(13)
Substance Abuse Treatment
(13)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series

Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years

Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Buprenorphine Use: The International Experience

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Contingency management among homeless, out-of-treatment men who have sex with men

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy

A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment

Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Using buprenorphine short-term taper to facilitate early treatment engagement

Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation

A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy

Suchergebnisse filtern